201 related articles for article (PubMed ID: 25209844)
1. Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Kuroda J; Mizutani S; Shimura Y; Maegawa S; Nagoshi H; Chinen Y; Tatekawa S; Tsukamoto T; Mizuno Y; Yamamoto-Sugitani M; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Ann Hematol; 2015 Apr; 94(4):687-9. PubMed ID: 25209844
[No Abstract] [Full Text] [Related]
2. Subcutaneous bortezomib: a step towards optimised drug use.
Mateos MV
Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
[No Abstract] [Full Text] [Related]
3. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
[No Abstract] [Full Text] [Related]
4. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
Barbee MS; Harvey RD; Lonial S; Kaufman JL; Wilson NM; McKibbin T; Hutcherson DA; Surati M; Valla K; Shah KS
Ann Pharmacother; 2013 Sep; 47(9):1136-42. PubMed ID: 24259728
[TBL] [Abstract][Full Text] [Related]
6. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
7. [Velcade for multiple myeloma. A new method of administration].
Perspect Infirm; 2012; 9(5):66. PubMed ID: 22978139
[No Abstract] [Full Text] [Related]
8. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
Obeid KM; Ferrara R; Sharma M
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
[No Abstract] [Full Text] [Related]
9. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
10. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
[No Abstract] [Full Text] [Related]
11. [Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].
Koike K; Morishige S; Fukami K; Taguchi K; Yakushiji K; Okamura T; Okuda S
Nihon Naika Gakkai Zasshi; 2011 Jan; 100(1):179-81. PubMed ID: 21387650
[No Abstract] [Full Text] [Related]
12. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
Terpos E
Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
[No Abstract] [Full Text] [Related]
13. Home administration of bortezomib: making a difference to myeloma patients' lives.
Meenaghan T; O'Dwyer M; Hayden P; Hayat A; Murray M; Dowling M
Eur J Oncol Nurs; 2010 Apr; 14(2):134-6. PubMed ID: 19818684
[No Abstract] [Full Text] [Related]
14. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
He Q; Zhao X; He Y; Tan D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib and restoration of chemosensitivity.
Gozzetti A
Nat Rev Clin Oncol; 2009 Nov; 6(11):15-c1; author reply 15-c2. PubMed ID: 19877369
[No Abstract] [Full Text] [Related]
16. [Subcutaneous bortezomib as a new promising way to successful maintenance therapy in multiple myeloma].
Grosicki S
Wiad Lek; 2012; 65(3):167-73. PubMed ID: 23289264
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Moreau P; Karamanesht II; Domnikova N; Kyselyova MY; Vilchevska KV; Doronin VA; Schmidt A; Hulin C; Leleu X; Esseltine DL; Venkatakrishnan K; Skee D; Feng H; Girgis S; Cakana A; van de Velde H; Deraedt W; Facon T
Clin Pharmacokinet; 2012 Dec; 51(12):823-9. PubMed ID: 23018466
[TBL] [Abstract][Full Text] [Related]
18. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
Moreau P; Coiteux V; Hulin C; Leleu X; van de Velde H; Acharya M; Harousseau JL
Haematologica; 2008 Dec; 93(12):1908-11. PubMed ID: 18768528
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
Benevolo G; Larocca A; Gentile M; Pregno P; Gay F; Botto B; Frairia C; Evangelista A; Morabito F; Boccadoro M; Vitolo U; Palumbo A
Cancer; 2011 May; 117(9):1884-90. PubMed ID: 21509765
[TBL] [Abstract][Full Text] [Related]
20. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Kamimura T; Miyamoto T; Takashima S; Yokota N; Chong Y; Ito Y; Akashi K
Int J Hematol; 2012 Oct; 96(4):525-7. PubMed ID: 22961216
[No Abstract] [Full Text] [Related]
[Next] [New Search]